Lipoprotein-associated phospholipase A2 and arterial stiffness evaluation in patients with inflammatory bowel diseases

Journal of Crohn's and Colitis

Volumn 8, Issue 9, 2014, Pages 936-944

  Theocharidou, Eleni ^a   Tellis, Constantinos C ^b   Mavroudi, Melachrini ^a   Soufleris, Konstantinos ^a   Gossios, Thomas D ^a   Giouleme, Olga ^a   Athyros, Vasilios G ^a   Tselepis, Alexandros D ^b   Karagiannis, Asterios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Arterial stiffness; Cardiovascular disease; Inflammatory bowel diseases; Lipoprotein associated phospholipase A2; Pulse wave velocity

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER; HEMOGLOBIN;

ADULT; ARTERIAL STIFFNESS; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; MEAN ARTERIAL PRESSURE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PULSE WAVE; SMOKING; ULCERATIVE COLITIS; ADOLESCENT; BLOOD; CARDIOVASCULAR DISEASES; CAROTID ARTERY; COMPLICATION; ENZYMOLOGY; FEMORAL ARTERY; INFLAMMATORY BOWEL DISEASE; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR; YOUNG ADULT; AGE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; LEUKOCYTE COUNT;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; FEMALE; FEMORAL ARTERY; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RISK FACTORS; VASCULAR STIFFNESS; YOUNG ADULT;

EID: 84906789710     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.01.016     Document Type: Article

References (43)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
2. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
3. Danesh J., Wheeler J.G., Hirschfield G.M., Eda S., Eiriksdottir G., Rumley A., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387-1397.
4. Roman M.J., Shanker B.A., Davis A., Lockshin M.D., Sammaritano L., Simantov R., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2399-2406.
5. Van Doornum S., McColl G., Wicks I.P. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?. Arthritis Rheum 2002, 46:862-873.
6. Bernstein C.N., Blanchard J.F., Houston D.S., Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001, 85:430-434.
7. Ha C., Magowan S., Accortt N.A., Chen J., Stone C.D. Risk of arterial thrombotic events in inflammatory bowel disease. Am J Gastroenterol 2009, 104:1445-1451.
8. Haapamaki J., Roine R.P., Turunen U., Farkkila M.A., Arkkila P.E. Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. J Crohns Colitis 2011, 5:41-47.
9. Rungoe C., Basit S., Ranthe M.F., Wohlfahrt J., Langholz E., Jess T. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut 2012, 62:689-694.
10. Theocharidou E., Gossios T.D., Giouleme O., Athyros V.G., Karagiannis A. Carotid intima-media thickness in patients with inflammatory bowel disease: a systematic review. Angiology 2014, [in press].
11. Aloi M., Tromba L., Di Nardo G., Dilillo A., Del Giudice E., Marocchi E., et al. Premature subclinical atherosclerosis in pediatric inflammatory bowel disease. J Pediatr 2012, 161:589-594.
12. Kayahan H., Sari I., Cullu N., Yuksel F., Demir S., Akarsu M., et al. Evaluation of early atherosclerosis in patients with inflammatory bowel disease. Dig Dis Sci 2012, 57:2137-2143.
13. Principi M., Mastrolonardo M., Scicchitano P., Gesualdo M., Sassara M., Guida P., et al. Endothelial function and cardiovascular risk in active inflammatory bowel diseases. J Crohns Colitis 2013, 7(10):e427-e433.
14. Laurent S., Cockcroft J., Van Bortel L., Boutouyrie P., Giannattasio C., Hayoz D., et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006, 27:2588-2605.
15. Katsiki N., Koumaras C., Athyros V.G., Karagiannis A. Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk. Angiology 2012, 63:9-11.
16. Cavalcante J.L., Lima J.A., Redheuil A., Al Mallah M.H. Aortic stiffness: current understanding and future directions. J Am Coll Cardiol 2011, 57:1511-1522.
17. Tellis C.C., Tselepis A.D. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta 2009, 1791:327-338.
18. Tselepis A.D., John C.M. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl 2002, 3:57-68.
19. Tsimikas S., Tsironis L.D., Tselepis A.D. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol 2007, 27:2094-2099.
20. Stafforini D.M., McIntyre T.M., Carter M.E., Prescott S.M. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem 1987, 262:4215-4222.
21. Markakis K.P., Koropouli M.K., Grammenou-Savvoglou S., van Winden E.C., Dimitriou A.A., Demopoulos C.A., et al. Implication of lipoprotein associated phospholipase A2 activity in oxLDL uptake by macrophages. J Lipid Res 2010, 51:2191-2201.
22. Gazi I., Lourida E.S., Filippatos T., Tsimihodimos V., Elisaf M., Tselepis A.D. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005, 51:2264-2273.
23. Sudhir K. Clinical review: lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. J Clin Endocrinol Metab 2005, 90:3100-3105.
24. Gregson J., Stirnadel-Farrant H.A., Doobaree I.U., Koro C. Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: a systematic review of the literature. Atherosclerosis 2012, 225:11-21.
25. Moutzouri E., Tsimihodimos V., Tselepis A.D. Inflammatory biomarkers and cardiovascular risk assessment. Current knowledge and future perspectives. Curr Pharm Des 2013, 19:3827-3840.
26. Tselepis A.D., Dentan C., Karabina S.A., Chapman M.J., Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol 1995, 15:1764-1773.
27. D'Haens G., Sandborn W.J., Feagan B.G., Geboes K., Hanauer S.B., Irvine E.J., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007, 132:763-786.
28. Sandborn W.J., Feagan B.G., Hanauer S.B., Lochs H., Lofberg R., Modigliani R., et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002, 122:512-530.
29. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
30. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Bohm M., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013, 34:2159-2219.
31. Andresdottir M.B., Sigurdsson G., Sigvaldason H., Gudnason V. Fifteen percent of myocardial infarctions and coronary revascularizations explained by family history unrelated to conventional risk factors. The Reykjavik Cohort Study. Eur Heart J 2002, 23:1655-1663.
32. Zanoli L., Cannavo M., Rastelli S., Di Pino L., Monte I., Di Gangi M., et al. Arterial stiffness is increased in patients with inflammatory bowel disease. J Hypertens 2012, 30:1775-1781.
33. Akdogan R.A., Durakoglugil M.E., Kocaman S.A., Cicek Y., Durakoglugil T., Ergul E., et al. Increased pulse wave velocity and carotid intima-media thickness in patients with ulcerative colitis. Dig Dis Sci 2013, 58(8):2293-2300.
34. Vlachopoulos C., Dima I., Aznaouridis K., Vasiliadou C., Ioakeimidis N., Aggeli C., et al. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation 2005, 112:2193-2200.
35. Toms T.E., Panoulas V.F., Douglas K.M., Nightingale P., Smith J.P., Griffiths H., et al. Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis?. Angiology 2011, 62:167-175.
36. Athyros V.G., Katsiki N., Doumas M., Karagiannis A., Mikhailidis D.P. Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review. Curr Med Res Opin 2013, 29(10):1263-1274.
37. Cosnes J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol 2004, 18:481-496.
38. van der H.F., Dijkstra A., Albersnagel F.A., Kleibeuker J.H., Dijkstra G. Active and passive smoking behaviour and cessation plans of patients with Crohn's disease and ulcerative colitis. J Crohns Colitis 2010, 4:125-131.
39. van der H.F., Dijkstra A., Weersma R.K., Albersnagel F.A., van der Logt E.M., Faber K.N., et al. Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2009, 15:1199-1207.
40. Athyros V.G., Tziomalos K., Katsiki N., Gossios T.D., Giouleme O., Anagnostis P., et al. The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study. Curr Vasc Pharmacol 2013, 11(5):779-784.
41. Haapamaki M.M., Gronroos J., Nurmi H., Irjala K., Peuravuori H., Nevalainen T.J. Value of blood tests including serum group IIA phospholipase A2 and bactericidal/permeability-increasing protein in Crohn's disease. Scand J Clin Lab Invest 2006, 66:585-593.
42. Peterson J.W., Dickey W.D., Saini S.S., Gourley W., Klimpel G.R., Chopra A.K. Phospholipase A2 activating protein and idiopathic inflammatory bowel disease. Gut 1996, 39:698-704.
43. Angel K., Provan S.A., Gulseth H.L., Mowinckel P., Kvien T.K., Atar D. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 2010, 55:333-338.